RATIONALE: FK506 binding protein (FKBP)12 is a known cis-trans peptidyl prolyl isomerase and highly expressed in the heart. Its role in regulating postnatal cardiac function remains largely unknown. METHODS AND RESULTS: We generated FKBP12 overexpressing transgenic (αMyHC-FKBP12) mice and cardiomyocyte-restricted FKBP12 conditional knockout (FKBP12(f/f)/αMyHC-Cre) mice and analyzed their cardiac electrophysiology in vivo and in vitro. A high incidence (38%) of sudden death was found in αMyHC-FKBP12 mice. Surface and ambulatory ECGs documented cardiac conduction defects, which were further confirmed by electric measurements and optical mapping in Langendorff-perfused hearts. αMyHC-FKBP12 hearts had slower action potential upstrokes and longer action potential durations. Whole-cell patch-clamp analyses demonstrated an ≈ 80% reduction in peak density of the tetrodotoxin-resistant, voltage-gated sodium current I(Na) in αMyHC-FKBP12 ventricular cardiomyocytes, a slower recovery of I(Na) from inactivation, shifts of steady-state activation and inactivation curves of I(Na) to more depolarized potentials, and augmentation of late I(Na), suggesting that the arrhythmogenic phenotype of αMyHC-FKBP12 mice is attributable to abnormal I(Na). Ventricular cardiomyocytes isolated from FKBP12(f/f)/αMyHC-Cre hearts showed faster action potential upstrokes and a more than 2-fold increase in peak I(Na) density. Dialysis of exogenous recombinant FKBP12 protein into FKBP12-deficient cardiomyocytes promptly recapitulated alterations in I(Na) seen in αMyHC-FKBP12 myocytes. CONCLUSIONS: FKBP12 is a critical regulator of I(Na) and is important for cardiac arrhythmogenic physiology. FKPB12-mediated dysregulation of I(Na) may underlie clinical arrhythmias associated with FK506 administration.
RATIONALE: FK506 binding protein (FKBP)12 is a known cis-trans peptidyl prolyl isomerase and highly expressed in the heart. Its role in regulating postnatal cardiac function remains largely unknown. METHODS AND RESULTS: We generated FKBP12 overexpressing transgenic (αMyHC-FKBP12) mice and cardiomyocyte-restricted FKBP12 conditional knockout (FKBP12(f/f)/αMyHC-Cre) mice and analyzed their cardiac electrophysiology in vivo and in vitro. A high incidence (38%) of sudden death was found in αMyHC-FKBP12mice. Surface and ambulatory ECGs documented cardiac conduction defects, which were further confirmed by electric measurements and optical mapping in Langendorff-perfused hearts. αMyHC-FKBP12 hearts had slower action potential upstrokes and longer action potential durations. Whole-cell patch-clamp analyses demonstrated an ≈ 80% reduction in peak density of the tetrodotoxin-resistant, voltage-gated sodium current I(Na) in αMyHC-FKBP12 ventricular cardiomyocytes, a slower recovery of I(Na) from inactivation, shifts of steady-state activation and inactivation curves of I(Na) to more depolarized potentials, and augmentation of late I(Na), suggesting that the arrhythmogenic phenotype of αMyHC-FKBP12mice is attributable to abnormal I(Na). Ventricular cardiomyocytes isolated from FKBP12(f/f)/αMyHC-Cre hearts showed faster action potential upstrokes and a more than 2-fold increase in peak I(Na) density. Dialysis of exogenous recombinant FKBP12 protein into FKBP12-deficient cardiomyocytes promptly recapitulated alterations in I(Na) seen in αMyHC-FKBP12 myocytes. CONCLUSIONS:FKBP12 is a critical regulator of I(Na) and is important for cardiac arrhythmogenic physiology. FKPB12-mediated dysregulation of I(Na) may underlie clinical arrhythmias associated with FK506 administration.
Authors: Hong-Bo Xin; Takaaki Senbonmatsu; Dong-Sheng Cheng; Yong-Xiao Wang; Julio A Copello; Guang-Ju Ji; Mei Lin Collier; Ke-Yu Deng; Loice H Jeyakumar; Mark A Magnuson; Tadashi Inagami; Michael I Kotlikoff; Sidney Fleischer Journal: Nature Date: 2002-03-21 Impact factor: 49.962
Authors: D Nuyens; M Stengl; S Dugarmaa; T Rossenbacker; V Compernolle; Y Rudy; J F Smits; W Flameng; C E Clancy; L Moons; M A Vos; M Dewerchin; K Benndorf; D Collen; E Carmeliet; P Carmeliet Journal: Nat Med Date: 2001-09 Impact factor: 53.440
Authors: Wei Tang; Christopher P Ingalls; William J Durham; Jessica Snider; Michael B Reid; Gangyi Wu; Martin M Matzuk; Susan L Hamilton Journal: FASEB J Date: 2004-08-02 Impact factor: 5.191
Authors: Q Wang; J Shen; I Splawski; D Atkinson; Z Li; J L Robinson; A J Moss; J A Towbin; M T Keating Journal: Cell Date: 1995-03-10 Impact factor: 41.582
Authors: Wendell S Akers; Jeremy D Flynn; George A Davis; Amy E Green; P Shane Winstead; Gunnar Strobel Journal: Pharmacotherapy Date: 2004-03 Impact factor: 4.705
Authors: D Woodrow Benson; Dao W Wang; Macaira Dyment; Timothy K Knilans; Frank A Fish; Margaret J Strieper; Thomas H Rhodes; Alfred L George Journal: J Clin Invest Date: 2003-10 Impact factor: 14.808
Authors: Joshua W Vincentz; Beth A Firulli; Kevin P Toolan; Dan E Arking; Nona Sotoodehnia; Juyi Wan; Peng-Sheng Chen; Corrie de Gier-de Vries; Vincent M Christoffels; Michael Rubart-von der Lohe; Anthony B Firulli Journal: Circ Res Date: 2019-08-01 Impact factor: 17.367
Authors: Beth A Firulli; Rajani M George; Jade Harkin; Kevin P Toolan; Hongyu Gao; Yunlong Liu; Wenjun Zhang; Loren J Field; Ying Liu; Weinian Shou; Ronald Mark Payne; Michael Rubart-von der Lohe; Anthony B Firulli Journal: Cardiovasc Res Date: 2020-03-01 Impact factor: 10.787
Authors: Jum-Suk Ko; Shuai Guo; Jonathan Hassel; Patricia Celestino-Soper; Ty C Lynnes; James E Tisdale; James J Zheng; Stanley E Taylor; Tatiana Foroud; Michael D Murray; Richard J Kovacs; Xiaochun Li; Shien-Fong Lin; Zhenhui Chen; Matteo Vatta; Peng-Sheng Chen; Michael Rubart Journal: Am J Physiol Heart Circ Physiol Date: 2018-04-20 Impact factor: 4.733
Authors: László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-12-19 Impact factor: 3.000